CVRx Reports Second Quarter 2021 Financial and Operating ResultsSecond Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year
MINNEAPOLIS, Aug. 04, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2021.
- Total revenue for the second quarter 2021 was $3.1 million, an increase of 150% over prior year quarter
- U.S. Heart Failure (HF) revenue for the second quarter of 2021 was $2.0 million compared to $0.07 million in the prior year quarter
- Closed Initial Public Offering (IPO) on July 2, 2021, raising net proceeds of approximately $133.3 million
- Martha Shadan appointed to the Company’s Board of Directors
- Successfully completed the first clinical procedure with BATwire, a new ultrasound-guided implant toolkit
“We are extremely pleased with our continued strong financial and operational performance during the quarter. We delivered topline growth of 150%, driven by a significant increase in the number of active implanting centers added in recent quarters, as well as the accelerated utilization of Barostim by existing customers. These results demonstrate the strong and growing adoption of Barostim by physicians and patients as a solution for heart failure,” said Nadim Yared, President and Chief Executive Officer of CVRx. “Looking forward, we are focused on driving growth by increasing patient flow at existing implanting centers, as well as increasing the number of new active implanting centers. To accomplish this, we will continue to invest to expand our commercial infrastructure and increase awareness of this life changing technology among physicians and patients. The closing of our IPO in July provides us with incremental capital to fuel that expansion and accelerate the adoption of Barostim.”
Second Quarter 2021 Financial and Operating Results
|Revenue by Geography|
|Three months ended June 30,|
|(dollars in thousands)|
|United States Revenue by Product Category|
|Three months ended June 30,|
|(dollars in thousands)|
|U.S. Heart Failure (HF)||$||2,001||$||65||NM|
|U.S. Legacy Hypertension||104||132||(21||)||%|
|Total U.S. Revenue||$||2,105||$||197||969||%|
NM – Not meaningful
Revenue increased by $1.9 million, or 150%, to $3.1 million for the three months ended June 30, 2021 compared to the three months ended June 30, 2020.
Revenue generated in the U.S. was $2.1 million for the three months ended June 30, 2021, an increase of $1.9 million, or 969%, over the three months ended June 30, 2020. HF revenue units in the U.S. totaled 67 and 2 for the three months ended June 30, 2021 and 2020, respectively. HF revenue in the U.S. totaled $2.0 million and $65,000 for the three months ended June 30, 2021 and 2020, respectively. The increase was primarily driven by continued growth following the commercial launch in 2020, which resulted in the expansion into new sales territories and increased physician and patient awareness of Barostim. As of June 30, 2021, the Company had a total of 31 active implanting centers, as compared to 19 as of March 31, 2021. Active implanting centers are customers that have completed at least one commercial HF implant in the last 12 months. The number of sales territories in the U.S. increased by two to a total of eight during the three months ended June 30, 2021.
Revenue generated in Europe was $1.0 million for the three months ended June 30, 2021, a decrease of $35,000, or 3.3%, over the three months ended June 30, 2020. Total revenue units in Europe decreased to 47 from 49 for the three months ended June 30, 2021 and 2020, respectively. The revenue decrease was primarily due to the impact of the COVID-19 pandemic. The number of sales territories in Europe remained consistent at six during the three months ended June 30, 2021.
Gross profit was $2.2 million for the three months ended June 30, 2021, an increase of $1.3 million, or 144%, over the three months ended June 30, 2020. Gross margin decreased to 70.8% for the three months ended June 30, 2021 compared to 72.4% for the three months ended June 30, 2020. Gross margin for the three months ended June 30, 2021 was lower due to a larger percentage of our revenue units coming from full systems, which require an IPG and a stimulation lead, as compared to individual IPG sales. This was partially offset by an increase in the average selling price.
R&D expenses increased $0.1 million, or 5.8%, to $2.3 million for the three months ended June 30, 2021 compared to the three months ended June 30, 2020. This change was primarily due to an increase in stock-based compensation expense from $0.01 million to $0.19 million for the three months ended June 30, 2020 and 2021, respectively.
SG&A expenses increased $3.8 million, or 207%, to $5.6 million for the three months ended June 30, 2021 compared to the three months ended June 30, 2020. The primary driver was an increase in compensation, including salaries and commissions, and other employee-related expenses, mainly as a result of increased headcount. In addition, stock-based compensation expense increased from $0.02 million to $0.43 million for the three months ended June 30, 2020 and 2021, respectively.
Other expense, net was $11.4 million for the three months ended June 30, 2021 compared to income of $0.03 for the three months ended June 30, 2020. This change was primarily driven by an $11.4 million increase in expense related to the increase in fair value of the Company’s convertible preferred stock warrants.
Net loss was $17.7 million, or $48.48 per share, for the three months ended June 30, 2021, compared to a net loss of $3.7 million, or $10.18 per share, for the three months ended June 30, 2020. Net loss per share was based on 366,066 and 360,238 weighted average shares outstanding for the second quarter of 2021 and 2020, respectively.
As of June 30, 2021, cash and cash equivalents were $47.1 million compared to $54.0 million as of March 31, 2021. Net cash used in operating and investing activities were $6.8 million for the three months ended June 30, 2021.
For the full year of 2021, the Company expects:
- Total revenue between $13.3 million and $13.9 million;
- Gross margin between 72.0% and 74.0%;
- Operating expenses between $34.0 million and $36.0 million;
For the third quarter of 2021, the Company expects to report total revenue between $3.3 million and $3.6 million.
Initial Public Stock Offering
On July 2, 2021, the Company closed its IPO of 8,050,000 shares of its common stock at a public offering price of $18.00 per share, which included 1,050,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for net proceeds from the offering, after deducting the underwriting discount and other offering expenses payable by CVRx, of approximately $133.3 million.
In connection with the IPO, on June 22, 2021, the Company effected a 1-for-39.548 reverse stock split of the Company’s common stock. Accordingly, all share and per-share amounts for all periods presented in this release, including the financial statements below, have been adjusted retroactively to reflect the reverse stock split.
The table below presents the Company’s balance sheet data as of June 30, 2021 on an actual basis and on a pro forma as adjusted basis to give effect to:
- the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 11,929,584 shares of common stock upon the closing of the IPO; and
- the sale of 8,050,000 shares of common stock in the IPO, after deducting the underwriting discount and estimated offering expenses.
|As of June 30, 2021|
|(in thousands, except share data)|
|Cash and cash equivalents||$||47,128||$||180,385|
|Convertible preferred stock warrant liability||19,051||-|
|Redeemable convertible preferred stock||329,983||-|
|Total stockholders’ equity (deficit)||$||(318,931||)||$||163,360|
|Shares of common stock outstanding||366,342||20,345,926|
Board of Directors Appointment
On July 12, 2021, the Company announced the appointment of Martha Shadan to its Board of Directors. With more than three decades of experience as a business leader in the life science industry, Ms. Shadan brings a long track record of success in helping to commercialize medical technology innovations for both start-up and large companies. Ms. Shadan currently serves as the president and CEO of Miach Orthopaedics, a developer of bioengineered surgical implants for connective tissue repair.
First Clinical Procedure with BATwire
In June 2021, the first BATwire procedure was performed in the U.S. as part of a clinical trial. BATwire is a new implant toolkit which enables an ultrasound-guided implant procedure of Barostim. The Company believes BATwire could potentially expand the Company’s addressable patient population by including those who are deemed clinically unfit for the current procedure. In addition, as a result of this simplified implantation process, the Company believes more physicians, including electrophysiologists, would be confident and comfortable implanting Barostim.
Webcast and Conference Call Information
The Company will host a conference call at 5:30 pm Eastern Time on August 4, 2021 to discuss results of the quarter as well as a question and answer session. To listen to the conference call on your telephone, please dial (833) 730-3980 for U.S. callers, or +1 (720) 405-2140 for international callers, approximately ten minutes prior to the start time and reference conference code 1659235. To listen to a live webcast, please visit the Investors section of the CVRx website at: https://ir.cvrx.com/news-events/events. The webcast replay will be available on the CVRx website for 12 months following completion of the call.
About CVRx, Inc.
CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including statements regarding our financial guidance regarding third quarter and full year 2021 results and expectations about adoption of our Barostim therapy. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “outlook,” “guidance,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
The forward-looking statements in this press release are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history of significant losses, which we expect to continue; our limited history operating as a commercial company and our dependence on a single product, BAROSTIM NEO; our ability to establish and maintain sales and marketing capabilities; our ability to demonstrate to physicians and patients the merits of our BAROSTIM NEO; any failure by third-party payors to provide adequate coverage and reimbursement for the use of BAROSTIM NEO; our competitors’ success in developing and marketing products that are safer, more effective, less costly, easier to use or otherwise more attractive than BAROSTIM NEO; any failure to receive access to hospitals; our dependence upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including the outbreak of the novel strain of coronavirus, COVID-19; any failure of clinical studies for future indications to produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere; product liability claims; future lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and ultimately unsuccessful; any failure to retain our key executives or recruit and hire new employees; and other important factors that could cause actual results, performance or achievements to differ materially from those that are found in “Part II, Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Mark Klausner or Mike Vallie
Westwicke, an ICR Company
Trevi Communications, Inc.
978.750.0333 / 617.835.0396
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
|June 30,||December 31,|
|Cash and cash equivalents||$||47,128||$||59,112|
|Accounts receivable, net||2,243||1,281|
|Prepaid expenses and other current assets||1,684||605|
|Total current assets||54,216||64,341|
|Property and equipment, net||820||410|
|Other non-current assets||26||26|
|Liabilities and Stockholders’ Equity (Deficit)|
|Current portion of long-term debt||1,333||—|
|Total current liabilities||25,044||7,977|
|Other long-term liabilities||884||777|
|Commitments and contingencies|
|Convertible preferred stock, $0.01 par value, 237,370,645 authorized as of
June 30, 2021 and December 31, 2020; 223,541,754 shares issued and
outstanding as of June 30, 2021 and December 31, 2020
|Stockholders’ equity (deficit):|
|Common stock, $0.01 par value, 625,217,795 authorized as of June 30, 2021 and
December 31, 2020; 366,342 and 360,412 shares issued and outstanding as of
June 30, 2021 and December 31, 2020, respectively
|Additional paid-in capital, common stock||59,311||58,624|
|Accumulated other comprehensive loss||(195||)||(190||)|
|Total stockholders’ equity (deficit)||(318,931||)||(293,238||)|
|Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)||$||55,062||$||64,777|
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
|Three months ended||Six months ended|
|June 30,||June 30,|
|Cost of goods sold||913||345||1,780||777|
|Research and development||2,255||2,131||4,005||4,400|
|Selling, general and administrative||5,627||1,834||10,087||4,128|
|Total operating expenses||7,882||3,965||14,092||8,528|
|Loss from operations||(5,672||)||(3,060||)||(9,889||)||(6,337||)|
|Other income (expense), net||(11,442||)||33||(15,234||)||137|
|Loss before income taxes||(17,722||)||(3,645||)||(26,332||)||(7,435||)|
|Provision for income taxes||(26||)||(22||)||(43||)||(45||)|
|Cumulative translation adjustment||(1||)||(11||)||(5||)||(21||)|
|Net loss per share, basic and diluted||$||(48.48||)||$||(10.18||)||$||(72.58||)||$||(18.06||)|
|Weighted-average common shares used to compute net
loss per share, basic and diluted